Previous chronotherapy studies have shown that the circadian pattern of blood pressure (BP) remains unchanged after either morning or evening dosing of several calcium channel blockers (CCB), including amlodipine, isradipine, verapamil, nitrendipine, and cilnidipine. This trial investigated the antihypertensive efficacy and safety profile of the slow-release, once-a-day nifedipine gastrointestinal therapeutic system (GITS) formulation administered at different times with reference to the rest-activity cycle of each participant. We studied 80 diurnally active subjects (36 men and 44 women), 52.1+/-10.7 yrs of age, with grade 1-2 essential hypertension, who were randomly assigned to receive nifedipine GITS (30 mg/day) as a monotherapy for eight weeks, either upon awakening in the morning or at bedtime at night. Patients with uncontrolled BP were up-titrated to a higher dose, 60 mg/day nifedipine GITS, for an additional eight weeks. BP was measured by ambulatory monitoring every 20 min during the day and every 30 min at night for 48 consecutive hours before and after therapy with either dose. The BP reduction after eight weeks of therapy with the lower dose of 30 mg/day was slightly, but not significantly, larger with bedtime dosing. The efficacy of 60 mg/day nifedipine GITS in non-responders to the initial 30 mg/day dose was twice as great with bedtime as compared to morning dosing. Moreover, bedtime administration of nifedipine GITS reduced the incidence of edema as an adverse event by 91%, and the total number of all adverse events by 74% as compared to morning dosing (p=0.026). Independent of the time of day of administration, a single daily dose of 30 mg/day of nifedipine GITS provides full 24 h therapeutic coverage. The dose-dependent increased efficacy and the markedly improved safety profile of bedtime as compared to morning administration of nifedipine GITS should be taken into account when prescribing this CCB in the treatment of essential hypertension.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/07420520701420683 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alcohol consumption and ambulatory blood pressure-lowering effect in male patients on clinic blood pressure-guided antihypertensive treatment.
Hypertens Res
January 2025
School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
In the present analysis, we investigated the association between alcohol consumption and ambulatory blood pressure (BP) control in male patients after 8 weeks of antihypertensive therapy with two dihydropyridine calcium channel blockers. The study participants were hypertensive (clinic systolic/diastolic BP of 140-179/90-109 mmHg and 24-hour ambulatory systolic/diastolic BP ≥ 130/80 mmHg) patients enrolled in a randomized controlled trial and treated with amlodipine 5-10 mg or nifedipine gastrointestinal therapeutic system (GITS) 30-60 mg once daily. Alcohol consumption was classified as non-drinkers and drinkers.
View Article and Find Full Text PDFA randomized controlled trial on the efficacy and safety of a calcium-channel blocker and an angiotensin-converting enzyme inhibitor in Chinese and European patients with hypertension.
Am J Hypertens
December 2024
IRCCS, Istituto Auxologic Italliano, Department of Cardiology, San Luca Hospital, Milan, Italy.
Article Synopsis
- - The study examined how effective and safe nifedipine GITS and ramipril are for treating hypertension in Chinese versus European patients through a post-hoc analysis of a multinational trial.
- - The research found that while both medications reduced blood pressure similarly across ethnic groups, ethnic differences impacted age, body mass index, and certain blood pressure measurements, and the response to treatment varied between the two groups.
- - The safety profiles noted significant differences, with fewer adverse events in Chinese patients taking nifedipine, while Europeans experienced more ankle edema with nifedipine and dry cough with ramipril.
Blood pressure variability assessed by office, home, and ambulatory measurements before and during antihypertensive drug treatment: a sub-analysis of the REVERENT randomized trial.
J Hypertens
August 2024
IRCCS, Istituto Auxologico Italiano, Department of Cardiology, San Luca Hospital.
Article Synopsis
- The study investigates how different methods of measuring blood pressure variability (OBP, HBP, and ABP) are related and agree with each other, particularly before and after starting treatment for high blood pressure.
- Participants included untreated hypertensive individuals who were given either ramipril or nifedipine GITS for 10 weeks, with their blood pressure variability assessed using standard deviation and coefficient of variation.
- Results showed only weak-to-moderate correlations between home and ambulatory BP measurements, indicating that while they can identify individuals with high blood pressure variability, they do not align well with office measurements.
Seasonal variation in ambulatory blood pressure control in patients on clinic blood pressure-guided antihypertensive treatment.
J Hypertens
May 2024
School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: We investigated seasonal variation in ambulatory blood pressure control in hypertensive patients on clinic blood pressure-guided antihypertensive treatment.
Methods: The study participants were hypertensive patients enrolled in an 8-week therapeutic study. Antihypertensive treatment was initiated with long-acting dihydropyridine calcium channel blockers amlodipine 5 mg/day or the gastrointestinal therapeutic system (GITS) formulation of nifedipine 30 mg/day, with the possible up-titration to amlodipine 10 mg/day or nifedipine-GITS 60 mg/day at 4 weeks of follow-up.
Dosing Time Matters? Nighttime vs. Daytime Administration of Nifedipine Gastrointestinal Therapeutic System (GITS) or Amlodipine on Non-dipper Hypertension: A Randomized Controlled Trial of NARRAS.
Front Cardiovasc Med
November 2021
Department of Internal Medicine, North China Electric Power University Hospital, Beijing, China.
Non-dipper hypertension is often characterized by a blunted decrease of nocturnal blood pressure (BP) and is associated with increased risk of target organ damage and cardiovascular (CV) events, while the optimal treatment strategy is yet to be established. This trial was designed to evaluate whether nocturnal BP reduction and arterial stiffness improvement differ from antihypertensive agents and time of administration. Young and middle-aged adults (18-65 years) with non-dipper hypertension were randomly assigned to nifedipine GITS (gastrointestinal therapeutic system) 30 mg or amlodipine besylate 5 mg once daily for 8 weeks, either taken in the morning or at night.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!